REG - IXICO plc - Further progress in HD consortium

IXICOAnnouncement

29/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240729:nRSc0989Ya&default-theme=true

RNS Number : 0989Y  IXICO plc  29 July 2024

 

29 July 2024

IXICO plc

("IXICO" or the "Company")

 

Further progress in HD consortium

Presentation of biomarker results and onboarding of new consortium partner

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company
delivering insights in neuroscience reports further progress in the
Huntington's disease imaging harmonization (HD-IH) consortium deploying
IXICO's AI powered IXIQ.Ai analysis platform to develop and validate imaging
biomarkers for HD.  HD-IH was previously announced as a partnership between
the CHDI Foundation, uniQure, PTC Therapeutics, and Asklepios
BioPharmaceutical, and IXICO is pleased to announce the onboarding of an
additional bio-pharma partner to HD-IH in June 2024.  Over the past year, the
expanding partnership has made significant progress in applying IXIQ.Ai to
more than 6,000 MRI scans available to the consortium and generating the data
required to demonstrate the utility of the obtained biomarker measurements as
clinical trial endpoints.

 

IXICO's Dr Marina Papoutsi presented preliminary findings at the annual HD-TC
conference in February 2024 in a poster entitled "Association between regional
volume change and clinical change in Huntington's disease HD-ISS Stage 2 and
Stage 3 participant". The presentation provides further evidence for the use
of brain volume changes measured with IXIQ.Ai as an alternative trial endpoint
to traditional clinical outcomes (surrogate endpoint). HD-IH continues to seek
additional partners to expand its biomarker development program.

 

Dr Robin Wolz, Chief Scientific Officer of IXICO, commented:

"We are delighted with the progress made in the HD-IH consortium over the past
year. The results presented at the HD-TC conference show how the initial data
generated via this partnership provides additional evidence of the impact that
MRI-based biomarkers have in HD clinical development. This further expansion
in the number of HD-IH biopharmaceutical partners demonstrates the value this
collaboration provides to the industry.

 

By completing the analysis of the available data over the remainder of 2024
and focusing on the resulting biomarker evidence, the consortium will provide
unique scientific understanding and insights for successful operational
implementation of those measurements in clinical development."

 

 

For further information please contact:

 

 IXICO plc                                                                                                          +44 (0) 20 3763 7499
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)    +44 (0) 20 7220 0500
 Giles Balleny / Dan Hodkinson (Corporate Finance)

 Michael F Johnson / Tamar Cranford Smith (Sales)

 

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.ixico.com/)  and
follow us on Twitter @IXICOnews

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQKABDOBKDCOB